pHLIP Technology
The results of biophysical studies led to the rational design of a novel class of delivery agents (pHLIPs®),
which can selectively target and deliver diagnostic and therapeutic molecules to acidic diseased tissues.
pHLIP® for imaging and fluorescence-guided surgical interventions
pHLIP® peptides labeled with optical, PET or SPECT probes are considered to be the first acidity markers.
We have shown targeting of diseased acidic tissue including primary tumors of various origins and
metastatic lesions, ischemia, inflammatory arthritis on animal models and targeting of cancerous lesions
on human tissue specimens. We proved that targeting is indeed pH-dependent. Metastatic and
aggressive tumors, which are more acidic, are targeted more efficiently compared to non-metastatic
ones, and tumor margins are stained with high accuracy. Currently, pHLIP® imaging agents are in the
process of clinical translation for PET diagnostic imaging of tumor acidity and fluorescence-guided
surgery.
pHLIP® for drug delivery
The membrane-associated folding of pHLIP® is accompanied by a release of free energy. We
demonstrated that this energy can be used to move polar, cell-impermeable cargo molecules across the
membrane into a cell. Such translocation is selective for low pH, and various types of cargo molecules
attached by cleavable to the inserting end of pHLIP® have thus been transported into cells and released
in the cytoplasm. Among translocated cargo molecules are fluorescent dyes, toxins, peptides and gene-
regulation agents. The polar and moderately hydrophobic molecules are moved across membrane, find
their cellular target and induce desired biological effect. The approach opens novel direction in drug
delivery.
|
Images of tumor spheroids and Trypan Blue assay (A). Fluorescence images of HeLa
tumor spheroids treated with the SNARF pHLIP ® peptide at pH 6.6 were acquired using 580 nm and 640
nm emission filters. The SNARF pHLIP ® peptide images of HeLa tumor spheroids are shown before and
immediately after the addition of cell-impermeable Trypan Blue, which clearly demonstrates
extracellular localization of SNARF fluorophore when pHLIP ® is inserted into plasma membrane of cells.
pH measured at the surfaces of cancer cells in tumors in vivo (B). Fluorescence spectra recorded from
tumors in live mice (skin is removed from the tumor site) 4 hours after administration of SNARF pHLIP ®
peptide as a single tail vein injection before and after IP injection of 125 mg of glucose.
pH imaging of cancer cells ex vivo (C). Fluorescence image obtained from a HeLa tumor specimen
treated ex vivo with the SNARF pHLIP ® peptide in the presence of glucose, followed by washing.
Images are from paper: Anderson et al, 2016, Proc Natl Acad Sci U S A.
|
pHLIP® nanotechnology
pHLIP® peptides find a variety of uses in nanotechnology applications. Multiple pHLIP® peptides can be
used to decorate a single nanoparticle, which can range in size from a few to hundreds of nanometers.
Nanocarriers decorated with pHLIP® peptides are biocompatible, can target tumors, and demonstrate
enhanced cellular uptake by cancer cells. Among the pHLIP® peptide-coated nanoparticles that have
been investigated are lipid, polymer, and metal-based nanomaterials.
|
Mechanism of pHLIP insertion into the cellular membrane (A). When the pHLIP (blue)
encounters healthy tissue where the extracellular pH is around pH 7.4, the protonatable residues of the
pHLIP (red circles) remain deprotonated and negatively charged, and the peptide resides at or near the
hydrophilic surface of the cellular membrane. Weakly bound to the membrane, the pHLIP is washed
from the membrane via normal perfusion and continues to circulate through the body. Cancer cells,
however, produce excess acidity as a consequence of their malfunctioning metabolisms and
overexpression of certain surface proteins, and pump these acidic byproducts out of the cell interior in
order to maintain comfortable conditions inside the cell, resulting in the acidification of tumor tissue.
When the pHLIP encounters tumor tissue, it senses the low extracellular pH at the cancer cell surface
(i.e., the concentration of protons (cyan circles) at the surface of the cellular membrane is high), and the
protonatable residues and negatively charged C-terminal carboxyl group of the pHLIP become neutrally
charged (green circles). The protonation leads to an increase in the overall hydrophobicity of the pHLIP,
increasing the affinity of the peptide to the hydrophobic core of the cellular membrane and triggering
the pHLIP to spontaneously fold into a helix and insert across the membrane, resulting in the formation
of a transmembrane helix. When the C-terminal protonatable residue and carboxyl group are then
exposed to the normal intracellular pH of the cell, they are deprotonated, again becoming negatively
charged, and anchor the pHLIP in the membrane.
Tethering cargo to the cell surface (B). A pHLIP can be used to target and tether cargo molecules to the
surfaces of cells in low pH environments. The cargo could be an optical marker, a PET or SPECT imaging
agent, or an antigen or protein delivered to induce certain cellular processes.
Translocating cargo across the membrane into the cytoplasm (C). A pHLIP can also be used for the
intracellular delivery of payloads, translocating cargo (green) across the membranes of cells with low
extracellular pH, such as those cells found in acidic, diseased tissue. These payloads are conjugated to
the membrane-inserting end of the pHLIP, typically via a cleavable link (magenta), and could include
toxins, chemotherapeutic agents, or agents to alter gene expression. The figures are from Review paper:
Wyatt et al., 2018, Trends Biotechnology.
|
|